Expert Review of Vaccines最新文献_第3页

Multiple antigen presenting system (MAPS): state of the art and potential applications. 多重抗原递呈系统（MAPS）：最新技术和潜在应用。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.1080/14760584.2023.2299384

Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer

{"title":"Multiple antigen presenting system (MAPS): state of the art and potential applications.","authors":"Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer","doi":"10.1080/14760584.2023.2299384","DOIUrl":"10.1080/14760584.2023.2299384","url":null,"abstract":"Introduction: Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.Areas covered: This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.Expert opinion: The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"196-204"},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants. 源于 Vero 细胞培养的日本脑炎疫苗的免疫原性和安全性：中国婴儿的 3 期研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-09-24 DOI: 10.1080/14760584.2024.2404633

Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu

{"title":"Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants.","authors":"Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu","doi":"10.1080/14760584.2024.2404633","DOIUrl":"10.1080/14760584.2024.2404633","url":null,"abstract":"Background: Japanese encephalitis (JE) is a severe infectious disease of the central nervous system. Vaccination with Vero cell culture-derived vaccines may effectively reduce JE incidence.Research design and methods: In this single-center, randomized, blinded, positive-controlled clinical trial in China involving 600 healthy infants aged 6-11 months, participants were divided into experimental and control groups administered JEV-PI and JEV-LI, respectively. Antibody titers were determined after 0- and 7-day immunization schedules. A booster dose followed 12 months later.Results: After primary vaccination and before booster vaccination, the positive conversion rate, geometric mean titer (GMT), and geometric mean increase (GMI) of JEV-PI-neutralizing antibodies exceeded those of JEV-LI. After booster immunization, the GMT and GMI of JEV-PI were higher than those of JEV-LI. After primary immunization, the local, systemic, and overall adverse reactions were of grades 1 and 2, with a low incidence of grade 3. After booster immunization, these differences were mainly grades 1 and 2, with no differences between JEV-PI and JEV-LI.Conclusion: JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.Trial registration: The trial was registered in the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj = 203130; registration number: ChiCTR2300074692; registration date: 14/08/2023).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"958-965"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of cell-based influenza vaccine in France. 法国细胞流感疫苗的成本效益。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-10-24 DOI: 10.1080/14760584.2024.2417854

Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo

{"title":"Cost-effectiveness of cell-based influenza vaccine in France.","authors":"Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo","doi":"10.1080/14760584.2024.2417854","DOIUrl":"10.1080/14760584.2024.2417854","url":null,"abstract":"Objectives: Annually in France, influenza results in over one million GP consultations, around 20,000 hospitalizations, and approximately 9,000 deaths. This study assesses the cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) for those under 65, which enhances effectiveness avoiding egg-adaptation, compared to egg-based quadrivalent influenza vaccine (QIVe).Methods: An age-structured susceptible-exposed-infected-recovered (SEIR) transmission model, calibrated to represent an average influenza season based on French data from 2011 to 2019, integrates a contact matrix estimating intergroup contact rates. Evaluating epidemiological, economic and utility outcomes, the model includes vaccine effectiveness and medical costs from the existing literature and French national data. Adjustments to quality of life due to infection and hospitalization are also included. Uncertainty is explored through scenario and sensitivity analyses.Results: Compared to QIVe, QIVc significantly reduces healthcare utilization and mortality, preventing 49,946 GP consultations, 1,087 hospitalizations, and 231 deaths in France. Despite an initial investment of 7.6 million euros, QIVc achieves a net saving of 12 million euros in healthcare expenditures, making it a dominant cost-saving strategy. Probabilistic sensitivity analyses indicate dominance in 78% of 10,000 simulations.Conclusions: Introducing cell-based influenza vaccines in the French immunization program prevents influenza cases, hospitalizations, death, while reducing costs versus egg-based influenza vaccines.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1020-1028"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune mechanisms targeting malaria transmission: opportunities for vaccine development. 针对疟疾传播的免疫机制：疫苗开发的机遇。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-06-25 DOI: 10.1080/14760584.2024.2369583

Geetha P Bansal, Nirbhay Kumar

{"title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development.","authors":"Geetha P Bansal, Nirbhay Kumar","doi":"10.1080/14760584.2024.2369583","DOIUrl":"10.1080/14760584.2024.2369583","url":null,"abstract":"Introduction: Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination.Areas covered: In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector.Expert opinion: To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"645-654"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant system AS01: from mode of action to effective vaccines. AS01佐剂系统：从作用模式到有效疫苗。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/14760584.2024.2382725

François Roman, Wivine Burny, Maria Angeles Ceregido, Béatrice Laupèze, Stéphane T Temmerman, Lucile Warter, Margherita Coccia

{"title":"Adjuvant system AS01: from mode of action to effective vaccines.","authors":"François Roman, Wivine Burny, Maria Angeles Ceregido, Béatrice Laupèze, Stéphane T Temmerman, Lucile Warter, Margherita Coccia","doi":"10.1080/14760584.2024.2382725","DOIUrl":"10.1080/14760584.2024.2382725","url":null,"abstract":"Introduction: The use of novel adjuvants in human vaccines continues to expand as their contribution to preventing disease in challenging populations and caused by complex pathogens is increasingly understood. AS01 is a family of liposome-based vaccine Adjuvant Systems containing two immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21. AS01-containing vaccines have been approved and administered to millions of individuals worldwide.Areas covered: Here, we report advances in our understanding of the mode of action of AS01 that contributed to the development of efficacious vaccines preventing disease due to malaria, herpes zoster, and respiratory syncytial virus. AS01 induces early innate immune activation that induces T cell-mediated and antibody-mediated responses with optimized functional characteristics and induction of immune memory. AS01-containing vaccines appear relatively impervious to baseline immune status translating into high efficacy across populations. Currently licensed AS01-containing vaccines have shown acceptable safety profiles in clinical trials and post-marketing settings.Expert opinion: Initial expectations that adjuvantation with AS01 could support effective vaccine responses and contribute to disease control have been realized. Investigation of the utility of AS01 in vaccines to prevent other challenging diseases, such as tuberculosis, is ongoing, together with efforts to fully define its mechanisms of action in different vaccine settings.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"715-729"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom. 模拟在英国使用改良疫苗接种不同 COVID-19 强化剂量疫苗策略可能产生的公共卫生和经济影响。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/14760584.2024.2383343

Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang

{"title":"Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.","authors":"Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang","doi":"10.1080/14760584.2024.2383343","DOIUrl":"10.1080/14760584.2024.2383343","url":null,"abstract":"Background: Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).Methods: A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.Results: Vaccination targeting individuals aged ≥ 65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths, 18,086 hospitalizations, 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.Conclusions: Targeting individuals aged ≥ 65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"730-739"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells. 从癌症疫苗中提取治疗性单克隆抗体 NEO-201，该抗体针对人类恶性肿瘤和免疫抑制细胞。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-09-01 DOI: 10.1080/14760584.2024.2397011

Massimo Fantini, Kwong Y Tsang, Philip M Arlen

{"title":"Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells.","authors":"Massimo Fantini, Kwong Y Tsang, Philip M Arlen","doi":"10.1080/14760584.2024.2397011","DOIUrl":"10.1080/14760584.2024.2397011","url":null,"abstract":"Introduction: Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.Areas covered: This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.Expert opinion: To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"812-829"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment. 疫苗可预防呼吸道感染的成人风险群体：英国环境概述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-11-17 DOI: 10.1080/14760584.2024.2428243

Charles Reynard, James Campling, Adam L Gordon, George Kassianos, Hui-Hsuan Liu, Alex Richter, Andrew Vyse, Dexter J Wiseman, Hannah Wright, Gillian Ellsbury

{"title":"Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment.","authors":"Charles Reynard, James Campling, Adam L Gordon, George Kassianos, Hui-Hsuan Liu, Alex Richter, Andrew Vyse, Dexter J Wiseman, Hannah Wright, Gillian Ellsbury","doi":"10.1080/14760584.2024.2428243","DOIUrl":"10.1080/14760584.2024.2428243","url":null,"abstract":"Introduction: Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to health and social care systems. In the UK, routine adult respiratory vaccination programs are in place. The objective of this article is to review the current evidence on the impact of four seasonal VPRIs in adults risk group definitions and to explore the strengths and limitations of current recommendations, and to identify evidence gaps for further research.Areas covered: Relevant evidence on UK data from surveillance systems, observational studies and publicly available government documents is collated and reviewed, as well as selected global data.Expert opinion: Disparities exist between adult risk group categories for different respiratory vaccination programs as defined in the current vaccination guidance. The burden of multiple respiratory pathogens signifies importance of routine multi-pathogen testing with the need for a resilient and large-scale national surveillance system. Further understanding of epidemiological trends and disease burden will help guide decision-making and planning of targeted strategies for disease prevention and control. Addressing inequalities in disease burden and vaccine coverage particularly in clinical risk groups, and promoting equitable vaccine access remain a priority.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1052-1067"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study. 单价 XBB.1.5 COVID-19 疫苗对七个欧洲国家老年人在奥米克龙 BA.2.86/JN.1 期间住院和死亡的有效性：VEBIS-EHR 网络研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-11-25 DOI: 10.1080/14760584.2024.2428800

Baltazar Nunes, James Humphreys, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Ida Rask Moustsen-Helms, Chiara Sacco, Massimo Fabiani, Jesús Castilla, Iván Martínez-Baz, Hinta Meijerink, Ausenda Machado, Patricia Soares, Rickard Ljung, Nicklas Pihlström, Anthony Nardone, Sabrina Bacci, Susana Monge

{"title":"Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study.","authors":"Baltazar Nunes, James Humphreys, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Ida Rask Moustsen-Helms, Chiara Sacco, Massimo Fabiani, Jesús Castilla, Iván Martínez-Baz, Hinta Meijerink, Ausenda Machado, Patricia Soares, Rickard Ljung, Nicklas Pihlström, Anthony Nardone, Sabrina Bacci, Susana Monge","doi":"10.1080/14760584.2024.2428800","DOIUrl":"10.1080/14760584.2024.2428800","url":null,"abstract":"Background: We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.Research design and methods: We linked electronic health records to create historical cohorts in Belgium, Denmark, Italy, Navarre (Spain), Norway, Portugal and Sweden. We included individuals aged ≥65-years eligible for the autumnal 2023 COVID-19 vaccine. Follow-up started when ≥80% of country-specific sequenced viruses were BA.2.86/JN.1 (4/dec/23 to 08/jan/24) and ended 25 February 2024. At study site level, we estimated the vaccine confounder-adjusted hazard ratio (aHR) of COVID-19 hospitalizations and deaths between individuals with ≥14 days after vaccination versus unvaccinated in autumn 2023, overall, by time since vaccination and age groups. VE was estimated as (1-pooled aHR)x100 with a random-effects model.Results: XBB.1.5 VE against COVID-19 hospitalizations was 50% (95%CI: 45 to 55) and 41% (95%CI: 35 to 46) in 65-79-year-olds and in ≥80-year-olds, respectively. VE against COVID19-related-death was 58% (95%CI: 42 to 69) and 48% (95%CI: 38 to 57), respectively, in both age groups. VE estimates against each outcome declined in all age groups over time.Conclusion: Monovalent XBB.1.5 vaccine had a moderate protective effect against severe and fatal COVID-19 likely caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1085-1090"},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. 间隔 10 年加强接种 TBE 疫苗的证据：对当前数据的评估。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-02-16 DOI: 10.1080/14760584.2024.2311359

Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen

{"title":"Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.","authors":"Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen","doi":"10.1080/14760584.2024.2311359","DOIUrl":"10.1080/14760584.2024.2311359","url":null,"abstract":"Introduction: Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.Areas covered: We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms 'Encephalitis, Tick-Borne/prevention and control' and 'Vaccination' for articles published in the English language.Expert opinion: Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3-5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"226-236"},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0